Urovant Sciences Ltd. (NASDAQ:UROV) management will conduct a conference call for 2nd November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.urovant.com
Earnings Expectation
Urovant Sciences Ltd. is reporting second quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, UROV is expected to report 2Q20 loss of $ 1.5 per share. For the full year, analysts anticipate top line of $ 7.73 million, while looking forward to loss of $ 5.86 per share bottom line.
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd.
